NASDAQ$ISRG
Intuitive Surgical Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Intuitive Surgical reported first quarter earnings with revenue increasing by 11% year-over-year, driven by growth in da Vinci procedure volume and an increase in the installed base of systems.
Intuitive Surgical announced its Q1 2024 financial results, highlighted by an 11% increase in revenue to $1.89 billion compared to Q1 2023. The company's GAAP net income attributable to Intuitive Surgical was $545 million, or $1.51 per diluted share. The growth was fueled by increased da Vinci procedure volume and expansion of the installed base.
- Worldwide da Vinci procedures grew approximately 16% compared to the first quarter of 2023.
- The company placed 313 da Vinci surgical systems, compared with 312 in the first quarter of 2023.
- The company grew its da Vinci surgical system installed base to 8,887 systems as of March 31, 2024, an increase of 14% compared with the first quarter of 2023.
- First quarter 2024 revenue increased 11% compared with the first quarter of 2023.
Headline financials
Revenue & EPS history
Intuitive Surgical · Revenue · Quarterly
$1.89B
Revenue by segment
Intuitive Surgical · $1.74B total across 3 segments · Q3 2023
- Instruments and accessories$1.07B+22.9%61.4%
- Systems$379M-10.9%21.8%
- Services$293M+12.7%16.8%
Forward guidance
Intuitive Surgical's core business measures remained healthy, with meaningful milestones achieved across several areas. The company is focused on delivering goals shared with customers, including improving patient outcomes.
Tailwinds
- Feedback from the measured da Vinci 5 launch is positive.
- Continued adoption of SP and Ion systems.
- Focus on improving patient outcomes.
- The company obtained CE mark certification for the da Vinci single-port (SP) surgical system.
- The Company obtained FDA clearance for da Vinci 5.
Headwinds
- The overall macroeconomic environment may impact customer spending and the Company’s costs, including the levels of inflation and interest rates.
- The conflict in Ukraine, conflicts in the Middle East, including Israel, disruption to the Company’s supply chain, including increased difficulties in obtaining a sufficient supply of materials.
- Curtailed or delayed capital spending by hospitals.
- The impact of global and regional economic and credit market conditions on healthcare spending.
- Risk that COVID-19 could lead to material delays and cancellations of, or reduced demand for, procedures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.9%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+3.1%
Avg return
30 days after
55%
40 / 73 earnings
Positive
+31.1%
Q2 2009
Best reaction
-16.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -3.5% | -9.3% | |
| Q4 2025 | -3.1% | +4.4% | -2.8% | |
| Q3 2025 | -2.3% | +19.1% | +21.4% | |
| Q2 2025 | +0.7% | +0.7% | -5.7% | |
| Q1 2025 | +1.9% | +7.4% | +12.7% | |
| Q4 2024 | -4.0% | +4.1% | +2.7% | |
| Q3 2024 | +9.3% | +8.6% | +10.7% | |
| Q2 2024 | +6.8% | +6.8% | +12.4% | |
| Q1 2024 | -2.1% | +0.8% | +6.6% | |
| Q4 2023 | -1.5% | +10.6% | +17.7% | |
| Q3 2023 | -3.1% | +0.7% | +10.8% | |
| Q2 2023 | -3.7% | -5.4% | -18.2% | |
| Q1 2023 | +11.0% | +11.7% | +16.1% | |
| Q4 2022 | -4.8% | -4.6% | -9.6% | |
| Q3 2022 | +11.1% | +14.9% | +37.2% | |
| Q2 2022 | -3.4% | -1.1% | +2.5% | |
| Q1 2022 | -16.7% | -19.3% | -27.7% | |
| Q4 2021 | -8.2% | -6.2% | -13.7% | |
| Q3 2021 | +2.3% | +2.8% | +8.1% | |
| Q2 2021 | +1.4% | +4.7% | +13.2% | |
| Q1 2021 | +9.9% | +7.9% | +2.6% | |
| Q4 2020 | -6.8% | -1.3% | +2.5% | |
| Q3 2020 | +0.2% | -2.4% | +0.3% | |
| Q2 2020 | +2.1% | +1.2% | +3.8% | |
| Q1 2020 | +3.0% | -2.8% | +1.8% | |
| Q4 2019 | -3.4% | -6.6% | +0.5% | |
| Q3 2019 | +6.8% | +1.0% | +7.4% | |
| Q2 2019 | +1.0% | +2.7% | -5.4% | |
| Q1 2019 | -6.5% | -4.7% | -6.6% | |
| Q4 2018 | -2.8% | -6.7% | +4.1% | |
| Q3 2018 | -7.1% | -6.6% | -4.5% | |
| Q2 2018 | -2.1% | -0.9% | -0.6% | |
| Q1 2018 | +12.6% | +9.1% | +9.5% | |
| Q4 2017 | +0.6% | -2.2% | -2.3% | |
| Q3 2017 | +4.3% | +4.8% | +10.8% | |
| Q2 2017 | -4.1% | -2.3% | +1.8% | |
| Q1 2017 | +5.1% | +5.9% | +11.9% | |
| Q4 2016 | +6.9% | +0.4% | +6.5% | |
| Q3 2016 | -4.0% | -4.4% | -7.7% | |
| Q2 2016 | +4.9% | +2.8% | +2.2% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | +4.4% | — | — | |
| Q2 2015 | +10.5% | — | — | |
| Q1 2015 | -6.5% | — | — | |
| Q4 2014 | -0.1% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +18.8% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | -6.5% | — | — | |
| Q3 2013 | -6.2% | — | — | |
| Q2 2013 | -5.5% | — | — | |
| Q1 2013 | -4.5% | — | — | |
| Q4 2012 | +11.6% | — | — | |
| Q3 2012 | +3.9% | — | — | |
| Q2 2012 | -9.3% | — | — | |
| Q1 2012 | +8.0% | — | — | |
| Q4 2011 | +0.4% | — | — | |
| Q3 2011 | +9.3% | — | — | |
| Q2 2011 | +10.3% | — | — | |
| Q1 2011 | +2.0% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q3 2010 | -7.9% | — | — | |
| Q2 2010 | +7.4% | — | — | |
| Q1 2010 | +0.2% | — | — | |
| Q4 2007 | -1.9% | — | — | |
| Q4 2009 | -1.9% | — | — | |
| Q3 2009 | -3.1% | — | — | |
| Q3 2008 | -3.1% | — | — | |
| Q2 2008 | +31.1% | — | — | |
| Q4 2008 | +31.1% | — | — | |
| Q2 2009 | +31.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro